Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
Tóm tắt
Breast cancers without HER2 amplification but still expressing this membrane protein constitute a new entity called HER2-low tumors. It is important to characterize them in terms of sensitivity to treatment and prognosis. To investigate chemosensitivity and long-term prognosis of HER2-low early breast cancer (eBC), compared to HER2-0 tumors, we retrospectively retrieved clinicopathological characteristics, response to treatment, and survival data from 511 patients treated for eBC with neoadjuvant chemotherapy (NAC) in a French cancer center between 2007 and 2018. Factors associated with the achievement of pathologic complete response (pCR) and survival were studied among hormone receptor positive (HR+) and negative (HR–) eBC. A total of 280 HR+ (61% HER2-low), and 231 HR– (28% HER2-low) eBC were included. We found classical clinicopathological factors usually associated with chemosensitivity and prognosis, in both HR+ and HR– eBC. By uni- and multivariable analysis, HER2 status (low vs 0) was not independently associated with pCR, either in HR+ or HR– eBC. Relapse free (RFS) and overall survival (OS) were not significantly different between HER2-low and HER2-0 among HR+ tumors. In contrast, among HR– negative tumors, RFS and OS were slightly better in HER2-0 eBC by univariable but not by multivariable analysis. In eBC patients treated with NAC, taking into account HR expression subtype and other current clinicopathological features, HER2-low tumors did not appear to have different chemosensitivity or prognosis, compared to their HER2-0 counterparts.
Tài liệu tham khảo
citation_journal_title=Lancet Lond Engl; citation_title=HER2-positive breast cancer; citation_author=S Loibl, L Gianni; citation_volume=389; citation_publication_date=2017; citation_pages=2415-2429; citation_doi=10.1016/S0140-6736(16)32417-5; citation_id=CR1
citation_journal_title=JCO Oncol Pract; citation_title=Management of early-stage human epidermal growth factor receptor 2-positive breast cancer; citation_author=S Pernas, SM Tolaney; citation_volume=17; citation_publication_date=2021; citation_pages=320-330; citation_doi=10.1200/OP.21.00020; citation_id=CR2
citation_journal_title=JCO Oncol Pract; citation_title=Current and future management of HER2-positive metastatic breast cancer; citation_author=O Martínez-Sáez, A Prat; citation_volume=17; citation_publication_date=2021; citation_pages=594-604; citation_doi=10.1200/OP.21.00172; citation_id=CR3
citation_journal_title=JCO Oncol Pract; citation_title=Mastering the use of novel anti-HER2 treatment options; citation_author=P Tarantino, D Trapani, G Curigliano; citation_volume=17; citation_publication_date=2021; citation_pages=605-606; citation_doi=10.1200/OP.21.00216; citation_id=CR4
citation_journal_title=J Clin Oncol Off J Am Soc Clin Oncol; citation_title=HER2-low breast cancer: pathological and clinical landscape; citation_author=P Tarantino; citation_volume=38; citation_publication_date=2020; citation_pages=1951-1962; citation_doi=10.1200/JCO.19.02488; citation_id=CR5
citation_journal_title=Future Horiz Cancer Discov; citation_title=Navigating the HER2-low paradigm in breast oncology: new standards; citation_author=P Tarantino, G Curigliano, SM Tolaney; citation_volume=12; citation_publication_date=2022; citation_pages=2026-2030; citation_doi=10.1158/2159-8290.CD-22-0703; citation_id=CR6
citation_journal_title=N Engl J Med; citation_title=Trastuzumab Deruxtecan in previously treated HER2-low advanced breast cancer; citation_author=S Modi; citation_volume=387; citation_publication_date=2022; citation_pages=9-20; citation_doi=10.1056/NEJMoa2203690; citation_id=CR7
citation_journal_title=Clin Cancer Res Off J Am Assoc Cancer Res; citation_title=Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis; citation_author=LM Spring; citation_volume=26; citation_publication_date=2020; citation_pages=2838-2848; citation_doi=10.1158/1078-0432.CCR-19-3492; citation_id=CR8
citation_journal_title=Lancet Lond Engl; citation_title=Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis; citation_author=P Cortazar; citation_volume=384; citation_publication_date=2014; citation_pages=164-172; citation_doi=10.1016/S0140-6736(13)62422-8; citation_id=CR9
citation_journal_title=Arch Pathol Lab Med; citation_title=American society of clinical oncology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer; citation_author=AC Wolff; citation_volume=131; citation_publication_date=2007; citation_pages=18-43; citation_doi=10.5858/2007-131-18-ASOCCO; citation_id=CR10
citation_journal_title=J Clin Oncol Off J Am Soc Clin Oncol; citation_title=Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline update; citation_author=AC Wolff; citation_volume=31; citation_publication_date=2013; citation_pages=3997-4013; citation_doi=10.1200/JCO.2013.50.9984; citation_id=CR11
citation_journal_title=J Clin Oncol Off J Am Soc Clin Oncol; citation_title=Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline focused update; citation_author=AC Wolff; citation_volume=36; citation_publication_date=2018; citation_pages=2105-2122; citation_doi=10.1200/JCO.2018.77.8738; citation_id=CR12
citation_journal_title=The Breast; citation_title=Pathological response and survival after neoadjuvant therapy for breast cancer: a 30-year study; citation_author=S Guiu; citation_volume=22; citation_publication_date=2013; citation_pages=301-308; citation_doi=10.1016/j.breast.2012.07.012; citation_id=CR13
citation_journal_title=Lancet Oncol; citation_title=Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials; citation_author=C Denkert; citation_volume=22; citation_publication_date=2021; citation_pages=1151-1161; citation_doi=10.1016/S1470-2045(21)00301-6; citation_id=CR14
citation_journal_title=JAMA Oncol; citation_title=Prognostic and biologic significance of ERBB2-low expression in early-stage breast cancer; citation_author=P Tarantino; citation_volume=8; citation_publication_date=2022; citation_pages=1177-1183; citation_id=CR15
citation_journal_title=NPJ Breast Cancer; citation_title=Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer; citation_author=F Schettini; citation_volume=7; citation_publication_date=2021; citation_pages=1; citation_doi=10.1038/s41523-020-00208-2; citation_id=CR16
citation_journal_title=Mod Pathol; citation_title=HER2-low breast cancer: incidence, clinicopathologic features, and survival outcomes from real-world data of a large nationwide cohort; citation_author=X Baez-Navarro, MR Bockstal, E-R Andrinopoulou, CHM Deurzen; citation_volume=36; citation_publication_date=2023; citation_doi=10.1016/j.modpat.2022.100087; citation_id=CR17
citation_journal_title=Cancer Res; citation_title=Abstract HER2–05: HER2–05 comprehensive genomic characterization of HER2-low breast cancer; citation_author=P Tarantino; citation_volume=83; citation_publication_date=2023; citation_pages=HER205; citation_doi=10.1158/1538-7445.SABCS22-HER2-05; citation_id=CR18
citation_journal_title=JAMA Oncol; citation_title=Clinicopathologic characteristics and prognosis of ERBB2-low breast cancer among patients in the national cancer database; citation_author=DS Peiffer; citation_volume=9; citation_publication_date=2023; citation_pages=500-510; citation_doi=10.1001/jamaoncol.2022.7476; citation_id=CR19
citation_journal_title=Breast Cancer Res Treat; citation_title=HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer; citation_author=L Moura-Leite; citation_volume=190; citation_publication_date=2021; citation_pages=155-163; citation_doi=10.1007/s10549-021-06365-7; citation_id=CR20
citation_journal_title=Eur J Cancer Oxf Engl; citation_title=Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy; citation_author=F Marmé; citation_volume=1990; citation_issue=53; citation_publication_date=2016; citation_pages=65-74; citation_doi=10.1016/j.ejca.2015.09.022; citation_id=CR21
citation_journal_title=J Clin Oncol Off J Am Soc Clin Oncol; citation_title=Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy; citation_author=JS Jeruss; citation_volume=26; citation_publication_date=2008; citation_pages=246-252; citation_doi=10.1200/JCO.2007.11.5352; citation_id=CR22
citation_journal_title=Eur J Cancer Oxf Engl; citation_title=Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy; citation_author=S Kang; citation_volume=1990; citation_issue=176; citation_publication_date=2022; citation_pages=30-40; citation_doi=10.1016/j.ejca.2022.08.031; citation_id=CR23
citation_journal_title=Eur J Cancer Oxf Engl; citation_title=Pathological complete response rate and disease-free survival after neoadjuvant chemotherapy in patients with HER2-low and HER2-0 breast cancers; citation_author=A Nonneville; citation_volume=1990; citation_issue=176; citation_publication_date=2022; citation_pages=181-188; citation_doi=10.1016/j.ejca.2022.09.017; citation_id=CR24
citation_journal_title=Breast Edinb Scotl; citation_title=Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer; citation_author=S Zhou; citation_volume=67; citation_publication_date=2023; citation_pages=1-7; citation_doi=10.1016/j.breast.2022.12.006; citation_id=CR25
citation_journal_title=Crit Rev Oncol Hematol; citation_title=Neoadjuvant chemotherapy in hormone receptor-positive/HER2-negative early breast cancer: when, why and what?; citation_author=R Torrisi; citation_volume=160; citation_publication_date=2021; citation_doi=10.1016/j.critrevonc.2021.103280; citation_id=CR26
citation_journal_title=Breast Cancer Tokyo Jpn; citation_title=The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status; citation_author=N Horisawa; citation_volume=29; citation_publication_date=2022; citation_pages=234-241; citation_doi=10.1007/s12282-021-01303-3; citation_id=CR27
citation_journal_title=Cancers; citation_title=HER2-low breast cancer: molecular characteristics and prognosis; citation_author=E Agostinetto; citation_volume=13; citation_publication_date=2021; citation_pages=2824; citation_doi=10.3390/cancers13112824; citation_id=CR28
citation_journal_title=Breast Cancer Res BCR; citation_title=Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-registry; citation_author=SP Gampenrieder; citation_volume=23; citation_publication_date=2021; citation_pages=112; citation_doi=10.1186/s13058-021-01492-x; citation_id=CR29
citation_journal_title=Cancers; citation_title=Prognostic value of HER2-low expression in non-metastatic triple-negative breast cancer and correlation with other biomarkers; citation_author=W Jacot; citation_volume=13; citation_publication_date=2021; citation_pages=6059; citation_doi=10.3390/cancers13236059; citation_id=CR30